Independent Data Monitoring Committee (DMC) to Review and Evaluate Patient Safety and Efficacy Data for Pivotal Phase 3 Trial of Galinpepimut-S in Patients with Acute Myeloid Leukemia in Second ...

Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA® (olaparib) Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis.

~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~ ~ Company Expects to Initiate Enrollment of Second Dose ...

As planned in the Protocol of the Study, the Independent Data Monitoring Committee (IDMC) met to review the unblinded safety and efficacy data of the first 90 patients after three months of treatment.

--Veru Inc. today announced that the Independent Data Monitoring Committee has conducted a planned conditional power analysis of the first 75 randomized patients in the Global Phase 3 COVID-19 ...

Regeneron Pharmaceuticals, Inc. received today a recommendation from the independent data monitoring committee for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current ...

An independent data monitoring committee has ruled that a phase 3 clinical trial investigating vidofludimus calcium for relapsing MS may continue as originally planned, according to the ...

Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., Feb. 11 and OSAKA, Japan ...

FLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies ...

NEW YORK (MarketWatch) -- Shares of NeoPharm neol surged 13% in pre-open trading Tuesday after the company said an independent data monitoring committee reviewed the data from a Phase III trial of ...

As planned in the Protocol of the Study, the Independent Data Monitoring Committee (IDMC) met to review the unblinded safety and efficacy data of the first 90 patients after three months of ...